Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 40, 2016 - Issue 6
120
Views
1
CrossRef citations to date
0
Altmetric
Short Communication

A Case of Fatal Agranulocytosis That Developed in a Patient with β-Thalassemia Major Treated with Deferiprone

, , , , , & show all
Pages 435-437 | Received 14 Feb 2016, Accepted 05 Dec 2016, Published online: 31 Mar 2017

References

  • Fisher SA, Brunskill SJ, Doree C, et al. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev. 2013;8:CD004839.
  • Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in β -thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738–3744.
  • Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876–1884.
  • Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118:330–336.
  • Henter JI, Karlen J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond–Blackfan anemia. Blood. 2007;109:5157–5159.
  • Masera N, Tavecchia L, Longoni DV, et al. Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination. Blood Transfus. 2011;9:462–465.
  • Huprikar N, Gossweiler M, Callaghan M, et al. Agranulocytosis with deferiprone treatment of superficial siderosis. BMJ Case Rep. 2013;2013. doi: 10.1136/bcr-2013-010099
  • al-Refaie FN, Veys PA, Wilkes S, et al. Agranulocytosis in a patient with thalassaemia major during treatment with the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one. Acta Haematol. 1993;89:86–90.
  • Sheikh-Taha M, Koussa S, Inati A, et al. Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient. Hemoglobin. 2007;31:499–501.
  • al-Refaie FN, Wonke B, Hoffbrand AV. Deferiprone-associated myelotoxicity. Eur J Haematol. 1994;53:298–301.
  • Elalfy M, Wali YA, Qari M, et al. Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis. Pediatr Blood Cancer. 2014;61:879–884.
  • El-Beshlawy AM, El-Alfy MS, Sari TT, et al. Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count. Eur J Haematol. 2014;92:337–340.
  • Vlachaki E, Ioannidou-Papagiannaki E, Tziomalos K, et al. Peripheral blood haematopoietic progenitor cells in patients with β thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy. Eur J Haematol. 2007;78:48–51.
  • Pontikoglou C, Papadaki HA. Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone. Hemoglobin. 2010;34:291–304.
  • Pati HP, Choudhry VP. Deferiprone (L1) associated neutropenia in β thalassemia major: an Indian experience. Eur J Haematol. 1999;63:267–268.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.